The optimal dosage of gemcitabine plus paclitaxel is decided by the dose limiting toxicity

2 trials

Sponsors

Tokai University School of Medicine Division of Breast and Endocrine Surgery Department of Surgery, Hiroshima Breast Cancer Study Group

Conditions

Breast Cancerbreast cancer

Phase 1

Phase I/II study of Gemcitabine plus weekly Paclitaxel with Metastatic Breast Cancer

Active, not recruitingJPRN-UMIN000006019

Tokai University School of Medicine Division of Breast and Endocrine Surgery Department of Surgerybreast cancer

Start: 2011-04-01Target: 47Updated: 2026-06-29

Unknown Phase

Phase 1/2 study of weekly paclitaxel and gemcitabine in patient with HER2 negative recurrent breast cancer

Active, not recruitingJPRN-UMIN000008848

Hiroshima Breast Cancer Study GroupBreast Cancer

Start: 2010-12-01Target: 45Updated: 2026-06-29